AstraZeneca (NYSE:AZN) recently appointed a new CEO who, besides having a business degree and spending years working in the pharmaceutical industry, was actually trained as a veterinarian. This inspired our health care analysts to wonder whether the most successful chief executives in the big pharma space are actually scientists and clinicians.

In the following video, Max Macaluso and David Williamson look for correlations between professional backgrounds and stock performance at some of the dominant players in big pharma, including Merck (NYSE:MRK), Pfizer (NYSE:PFE), and Eli Lilly (NYSE:LLY).

David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.